PARP1 and B-cell chronic lymphocytic leukemia: Altogether, these data clearly indicate that Atm-deficient CLL displays an actionable dependence on PARP and implicate PARP inhibitors as a potential further modality in the treatment armamentarium for ATM-deficient high-risk human CLL.